Come si colloca il rapporto 2269 N di PE rispetto ai suoi colleghi?

2269 N ha un buon valore in base al suo rapporto Price-To-Earnings ( 13.7 x) rispetto alla media dei peer ( 34.8 x).

Come si colloca il 2269 N's PE Ratio rispetto ad altre aziende del Global Life Sciences settore?

2269 N ha un buon valore in base al suo rapporto Price-To-Earnings ( 13.7 x) rispetto alla media del settore Global Life Sciences ( 33.6 x).

Qual è il 2269 N PE Ratio rispetto al suo Fair PE Ratio? Si tratta del PE Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

Dati insufficienti per calcolare il Fair Ratio di 2269 N Price-To-Earnings per l'analisi di valutazione.

Qual è il prezzo equo di 2269 N se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

2269 N ( MX$62.53 ) viene scambiato al di sotto della nostra stima del [[fair value]] ( MX$130.21 )

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Dati insufficienti per mostrare la previsione dei prezzi.

WuXi Biologics (Cayman) (BMV:2269 N) - Prezzo delle azioni, notizie e analisi

2269 N Panoramica delle azioni

An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. Maggiori dettagli

2269 N analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	3/6
Prestazioni passate	3/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 52% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 17.12% all'anno

Gli utili sono cresciuti del 1.7% nell'ultimo anno

Analisi del rischio

Le azioni sono altamente illiquide

WuXi Biologics (Cayman) Inc. Concorrenti

Medpace Holdings

NasdaqGS:MEDP

US$10.1b

Bruker

NasdaqGS:BRKR

US$8.1b

Pharmaron Beijing

SZSE:300759

CN¥45.8b

Hangzhou Tigermed Consulting

SZSE:300347

CN¥51.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per WuXi Biologics (Cayman)
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$62.53
Massimo di 52 settimane	HK$62.53
Minimo di 52 settimane	HK$62.53
Beta	0.66
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	n/a
3Variazione a 3 anni	-74.45%
Variazione a 5 anni	n/a
Variazione dall'IPO	-73.63%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	2269 N	MX Life Sciences	MX Mercato
7D	0%	0%	0%
1Y	n/a	0%	0%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato 2269 N rispetto al settore MX Life Sciences.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di 2269 N rispetto al mercato MX.

Volatilità dei prezzi

Is 2269 N's price volatile compared to industry and market?
2269 N volatility
2269 N Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Prezzo delle azioni stabile: 2269 N non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 2269 N nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2014	12,397	Chris Chen	www.wuxibiologics.com

WuXi Biologics (Cayman) Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di WuXi Biologics (Cayman) con la sua capitalizzazione di mercato?
2269 N statistiche fondamentali
Capitalizzazione di mercato	Mex$132.67b
Guadagni(TTM)	Mex$9.71b
Ricavi(TTM)	Mex$38.71b

13.7x

Rapporto P/E

3.4x

Rapporto P/S

2269 N è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
2269 N Conto economico (TTM)
Ricavi	CN¥16.55b
Costo del fatturato	CN¥9.68b
Profitto lordo	CN¥6.87b
Altre spese	CN¥2.72b
Guadagni	CN¥4.15b

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

Mar 26, 2024

Utile per azione (EPS)	0.99
Margine lordo	41.51%
Margine di profitto netto	25.08%
Rapporto debito/patrimonio netto	7.7%

Come si è comportato 2269 N nel lungo periodo?

Vedi performance storica e confronto

2269 N Panoramica delle azioni

Premi

Analisi del rischio

WuXi Biologics (Cayman) Inc. Concorrenti

NasdaqGS:MEDP

US$10.1b

NasdaqGS:BRKR

US$8.1b

SZSE:300759

CN¥45.8b

SZSE:300347

CN¥51.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Investor sentiment deteriorates as stock falls 26%

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Less than half of directors are independent

CEO & Executive Director recently sold Mex$45m worth of stock

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

CEO & Executive Director recently bought Mex$102m worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

CEO & Executive Director recently sold Mex$88m worth of stock

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

Insider recently bought Mex$9.2m worth of stock

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Executive VP recently sold Mex$275m worth of stock

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform